CEO of Amicus Therapeutics Buys 75,000 Shares at $6.10, Selling 75,000 at $14.31 Amid Market Dip and Rising Social‑Media Buzz—Insider Confidence Signals Possible Short‑Term Upswing but Regulatory Risks Remain
CEO Campbell Bradley’s $6.10 buy of 75k Amicus shares signals short‑term confidence and a growing long‑term stake—watch for the next clinical catalyst.
3 minutes to read